News
It’s no secret that obesity is becoming an epidemic in the United States. It’s estimated that by 2030, 50 percent of ...
Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...
Apple Fitness Plus is one of CNET’s favorite workout apps thanks to its versatility and various exercise selections. It's affordable at only $11 a month, giving you access to thousands of workouts for ...
Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...
Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...
Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...
Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America ...
Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...
Yes, extreme weight loss can affect your skin. Shop the best expert-recommended skin care products to help with weight loss ...
“From 2019 to 2024, the percentage of adult patients with a diagnosis of overweight or obesity increased 50.7 percent, and ...
A recent study aimed to assess evidence on the safety and complications of preoperative glucagon-like peptide-1 (GLP-1) ...
The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results